Skip to main content

Preview of EULAR 2019 Abstracts

Jun 12, 2019 3:24 am

EULAR 2019 begins today in Madrid and features over 2000 presentations.  After an initial review of titles and abstracts, I’ve compiled a hit list of presentations of interest to me and hopefully other practicing rheumatologists.  

EULAR will be rolling out many new “guidelines” reports including those addressing rheumatoid arthritis (RA) treatment; immune-related adverse events with checkpoint inhibitors, Sjogrens syndrome and more.

Late-breaking abstracts will be presented on Saturday morning (June 15th) and will include reports on filgotinib (Finch3), secukinumab (FUTURE 5), HLA-DRB1 alleles and responses to Abatacept or Adalimumab, Ultra-low dose rituximab and more.  

Here are some abstracts I’ll be watching (with links to EULAR Abstract site). Which of these interests you?





Two regimens of Rituximab in Scleroderma associated interstitial lung disease

Appears to improve Lung function


KAWAKINRA study: A pilot trial of anakinra in patients with IVIg-resistant Kawasaki disease

Rare disorder with good results in refractory disease. Dosing issues?


Randomized, double blind, placebo controlled trial of Steroids in Hand OA

Looks like it works? But what about adverse effects?


Riociguat in SSc associated ILD

 Anti-fibrotic drug shows some benefit in SSc lung disease



TOLEDEO study – Spacing ABA or TCZ to find the lowest effective dose in RA patients

Looks like less drug therapy carried a high risk of failure


Registry data on long-term outcomes and treatment efficacy in the TRAPS patients

IL-1 inhibitors much more effective than etanercept


Statins reduce relapse rates in Takayasu arteritis

A novel adjunctive therapy?


Fenebrutinib vs. Adalimumab in RA

BTK inhibitor works in MTX- & TNF-IR patients


Implated Vagal nerve stimulator in rheumatoid arthritis

Only 14 patients but novel, and looks effective


Tildrakizumab in active PsA patients

Data on 3rd IL-23 inhibitor


Maxmize Study: Secukinumab on Axial Manifestations in Psoriatic arthritis

Secukinumb works on the Axial outcomes of PsA pts with Spondylitis


 Measures of psoriasis severity and the risk of PsA

Skin severity predicts risk of PsA


 Characterization of psoriatic arthritis and nail psoriasis

 CORRONA - Nail disease predicts worse disease activity


Ultrasound application in Extracranial GCA

 Axillary US correlates with PET findings


EULAR recommendations for the management of irAE

 One of many EULAR recommendations at this meeting


 EULAR Recommendations for the Management of Sjogrens 



The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.